SL-164 is an analogue of methaqualone developed in the late 1960s by a team at Sumitomo. SL-164 has similar sedative, hypnotic and anticonvulsant properties to the parent compound, but was never marketed for clinical use. This product is intended for laboratory research purposes only and are not to be used for any other purposes.
Methylmethaqualone (MMQ) is a quinazolinone and a kind of methaqualone that has similar sedative and hypnotic properties to its parent compound (resulting from its agonist activity at the β subtype of the GABAA receptor), and is around the same potency. Methylmethaqualone differs from methaqualone by 4-methylation on the phenyl ring. It was made illegal in Germany in 1999 and listed by the DEA as a “drug of forensic interest” at about the same time, but little other information is available. It would appear that this compound was sold on the black market in Germany as a designer drug kind of methaqualone. Animal studies of methylmethaqualone have shown it to produce convulsions at only slightly above the effective sedative dose,and anecdotal reports from human users have confirmed that it can have a pro-convulsive effect, which has potential to make this compound particularly hazardous if taken in excessive doses